Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ: GOVX )

1.670 +0.040 (+2.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 820,730
Open 1.650
Bid (Size) 1.760 (3)
Ask (Size) 1.830 (50)
Prev. Close 1.630
Today's Range 1.555 - 1.710
52wk Range 1.090 - 11.18
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy Supply Chain
Exposures Supply Chain
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness 
Via TheNewswire.com
Topics Economy Supply Chain
Exposures Supply Chain

Performance

YTD
-32.66%
-32.66%
1 Month
-21.96%
-21.96%
3 Month
-44.52%
-44.52%
6 Month
-74.70%
-74.70%
1 Year
-23.09%
-23.09%

More News

Read More
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
Via NewMediaWire
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
Via TheNewswire.com
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
Via NewMediaWire
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Via TheNewswire.com
Topics Supply Chain
Exposures Supply Chain
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Via TheNewswire.com
Exposures Product Safety
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
Via TheNewswire.com
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
Via NewMediaWire
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
Via TheNewswire.com
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
Via NewMediaWire
Exposures COVID-19
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
Via TheNewswire.com
Exposures COVID-19
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Via NewMediaWire
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Via TheNewswire.com
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Via NewMediaWire
Topics Supply Chain
Exposures Supply Chain
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Via TheNewswire.com
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Via NewMediaWire
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Via NewMediaWire
Exposures Product Safety
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Via NewMediaWire
Exposures COVID-19
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Via TheNewswire.com
Exposures COVID-19
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Via NewMediaWire
Exposures COVID-19
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Via TheNewswire.com
Exposures COVID-19
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
Via NewMediaWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.